LOW MOLECULAR WEIGHT HEPARIN MARKET ANALYSIS

Low Molecular Weight Heparin Market, by Drug (Enoxaparin, Dalteparin, Nadroparin, Bemiparin, Tinzaparin, and Others), by Packaging (Multi-vials and Prefilled Syringes), by Application (Deep Vein Thrombosis, Acute Coronary Syndrome (ACS), Pulmonary Embolism and Atrial Fibrillation), by End User (Hospitals (Private and Public), Clinics, and Home), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Aug 2022
Code : CMI1491
Pages :218
Formats :
Excel and PDF
Industry : Biotechnology

Market Challenges And Opportunities

Restraints & Challenges:

Adverse effect of low molecular weight heparin

Global Low Molecular Weight Heparin Market: Restraint

The major factors that hinder growth of the global low molecular weight heparin market include adverse effect of low molecular weight heparin. Heparin induced thrombocytopenia (HIT), an adverse reaction occurring during treatment with heparin, is associated with inconsistent increase in the clotting causing further complications. Heparin-induced thrombocytopenia (HIT) is an adverse reaction that can occur during treatment with heparin. Increasing epidemic of Heparin-induced thrombocytopenia (HIT) due to application of heparin is restricting the growth of market. For instance, according to the data published in American Society of Hematology in 2017, Heparin-induced thrombocytopenia (HIT) is heparin’s most clinically relevant non-hemorrhagic complication. Furthermore, adults receiving heparin formulation for medical or general surgical indications are at higher risk for HIT than pediatric or obstetric patients.

Low Molecular Weight Heparin Market Report Snapshots